Oncology · Colorectal CancerTrial Updateclinicalmid-term

Study on Biomarkers for Predicting Recurrence in Colorectal Cancer Launched

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:31:24 AM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This study addresses a critical gap in colorectal cancer management by exploring biomarkers that could enhance predictive capabilities for recurrence and metastasis. The outcomes may significantly influence treatment strategies and the development of precision medicine approaches in oncology. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 14 ranked evidence items (9 high-relevance).

Strategic Assessment

The findings could inform future therapeutic developments and diagnostic tools, enhancing precision medicine approaches in colorectal cancer. The strongest clinical anchor is A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study) (ClinicalTrials.gov), sub-indication match (colorectal cancer). In colorectal cancer, 5 regulatory and 1 competitive items passed relevance filtering for colorectal cancer patients.

Competitive Pressure

The most relevant competitive pressure comes from New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy (Humanexa Signals) — sub-indication match (colorectal cancer). This research addresses a significant unmet need in colorectal cancer management, potentially impacting treatment strategies and patient outcomes.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. If the study yields robust biomarkers, it could lead to new regulatory pathways for diagnostics and therapeutics, impacting approval processes and compliance requirements.

Key Risks

Elevated medium regulatory exposure for colorectal cancer patients could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful identification of predictive biomarkers could lead to new diagnostic tools and therapies, potentially increasing market share for companies involved in colorectal cancer treatments.
Upside for colorectal cancer patients may improve if An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
The findings could inform future therapeutic developments and diagnostic tools, enhancing precision medicine approaches in colorectal cancer.

What Would Change This Assessment

This becomes more urgent if Monitor results from the study for advancements in biomarker identification and predictive modeling in colorectal cancer.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy
Humanexa Signalshigh relevance
Sub-indication match (colorectal cancer)
KIBRA identified as a tumor suppressor in osteosarcoma via Wnt/β-catenin inhibition
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

colorectal cancer patients
oncology drug developers
biomarker research firms

Commercial impact

medium

Successful identification of predictive biomarkers could lead to new diagnostic tools and therapies, potentially increasing market share for companies involved in colorectal cancer treatments.

Regulatory impact

medium

If the study yields robust biomarkers, it could lead to new regulatory pathways for diagnostics and therapeutics, impacting approval processes and compliance requirements.

What to watch

Monitor results from the study for advancements in biomarker identification and predictive modeling in colorectal cancer.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.